Selective induction hyperthermia following transcatheter arterial embolization with a mixture of nano-sized magnetic particles (ferucarbotran) and embolic materials: feasibility study in rabbits.
OBJECTIVE
To evaluate the possibility of selective hyperthermia following transcatheter arterial embolization (TAE) with ferucarbotran using a newly developed inductive heating (IH) device.


METHODS
Twelve Japanese white rabbits were separated into four groups: those treated with TAE using a mixture of ferucarbotran and lipiodol (F-L group); those treated with ferucarbotran and gelatin sponge powder; those treated with saline and lipiodol; and a control group. These four groups received IH. Nine rabbits with renal VX2 carcinoma were separated into three groups: IH after TAE (IH-TAE tumor), TAE without IH (TAE tumor), and no treatment (control tumor). The temperature of the tumor was kept at 45 degrees C for 20 min. The therapeutic effect was pathologically evaluated by TUNEL staining.


RESULTS
In the heating rates of the kidney, the F-L group showed significantly greater values than the group in which iron was not used. In the IH-TAE tumor group, tumors could be selectively heated. In TUNEL staining, the IH-TAE tumor and TAE tumor groups showed significantly greater values of apoptosis rate than in the control tumor group.


CONCLUSIONS
IH following TAE with a mixture of ferucarbotran and lipiodol was capable of inducing selective hyperthermia with our device. However, further investigation is needed to confirm its safety and effectiveness in the treatment of malignant neoplasms in humans.
Takamatsu
Shigeyuki
S
Department of Radiology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8641, Japan. shiget@rad.m.kanazawa-u.ac.jp
Matsui
Osamu
O
Gabata
Toshifumi
T
Kobayashi
Satoshi
S
Okuda
Miho
M
Ougi
Takahiro
T
Ikehata
Yoshio
Y
Nagano
Isamu
I
Nagae
Hideo
H
D000818:Animals; D016009:Chi-Square Distribution; D003287:Contrast Media / Q000008:administration & dosage*; D003911:Dextrans; D004195:Disease Models, Animal; D004621:Embolization, Therapeutic / Q000379:methods*; D005240:Feasibility Studies; D052203:Ferrosoferric Oxide; D005781:Gelatin Sponge, Absorbable / Q000008:administration & dosage; D006490:Hemostatics / Q000008:administration & dosage*; D006979:Hyperthermia, Induced; D007459:Iodized Oil / Q000008:administration & dosage*; D007501:Iron / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D058185:Magnetite Nanoparticles; D008297:Male; D053758:Nanoparticles; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000628:therapy*; D010087:Oxides / Q000008:administration & dosage*; D011817:Rabbits; D012965:Sodium Chloride / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed
D003287:Contrast Media; D003911:Dextrans; D006490:Hemostatics; D058185:Magnetite Nanoparticles; D010087:Oxides; D012965:Sodium Chloride; D007459:Iodized Oil; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide